Skip to main content
. 2021 Oct 20;11:756326. doi: 10.3389/fonc.2021.756326

Figure 4.

Figure 4

Diagnostic performance of the eHCC nomogram in the test set. (A) The risk score was significantly increased in the early HCC samples versus the HBVLD group (p = 2.7×10–7). (B) Area under the receiver operating characteristic curve (AUROC) of eHCC nomogram in the test set. Data were AUROC (95% CI). (C) Calibration curves of the eHCC nomogram in the test set. The x-axis represented the predicted probability of HCC risk from nomogram. The y-axis represented the actual HCC rate. The blue diagonal dotted line represented a perfect performance by an ideal nomogram. The red dotted line represented the performance of the eHCC nomogram, and the green solid line represented bootstrap-corrected performance of eHCC nomogram. (D) Decision curve analysis (DCA) of the nomogram predicted early HCC in the test set. The x-axis indicated the threshold probability, and the y-axis indicated the net benefit. The blue curve represented the eHCC nomogram. The red line indicated the assumption that all patients were HCC. The horizontal green line indicated the assumption that there were early HCC. eHCC, early hepatocellular carcinoma.